Skip to main content

Table 4 Adverse events possibly related to HDM/SCT (Grade >2)

From: Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial

Toxicity

BD + HDM/SCT (n = 28)

HDM/SCT (n = 28)

Pvalue

Nausea or vomiting

8 (28.6%)

10 (35.7%)

0.78

Diarrhea

6 (21.4%)

7 (25%)

1.0

Mucositis

5 (17.9%)

7 (25%)

0.75

Hepatic

5 (17.9%)

5 (17.9%)

1.0

Renal

4 (14.3%)

6 (21.4%)

0.73

Cardiac

3 (10.7%)

6 (21.4%)

0.47

Febrile neutropenia

9 (32.1%)

7 (25%)

0.77

Sepsis

0

2 (7.1%)

0.5

  1. BD, bortezomib in combination with dexamethasone; HDM/SCT, high dose melphalan and autologous stem cell transplantation.